Feedback Share Discussion Threads

[dplewis1] 17/10/2019 08:04

Decent so far! 1.35 paid

[dave4545] 17/10/2019 07:40

Thanks for the heads up on this one lewis.

[dplewis1] 17/10/2019 07:05

Bleepa 'clearly has applications across the healthcare sector, not only in individual hospital settings but also in community and cross site clinical settings'Also TexRad update before year end.

[dplewis1] 17/10/2019 07:03

Today looks like it may be a good day for FDBK

[ged5] 16/10/2019 13:58

Are you getting old LR2 or just doing too much?

I thought I'd seen a reference to TexRAD in Singapore.

"A further UCL study was presented at the International Society for Magnetic Resonance in Medicine (ISMRM 2016) in Singapore which demonstrated the application of TexRAD analysis of mp-MRI in peripheral zone prostate cancers in 66 patients."



Like others I think we all know the quality of TexRAD but we've seen enough research papers to be totally convinced.

What we need now is a commercial application. If Dr. Tom has done his job properly and he is true to his word about making an announcement on TexRAD and the outcome of the strategic review in due course then I hope it will be about a commercial use of TexRAD.

[hazl] 16/10/2019 09:40

w'e at @FBKmed
are very proud to be partnering with @FutureProcessin
to create #Bleepa #ConnectedCare

#AxeTheFax #PurgeThePager #BleepaMe
#DigitalTransformation #NHSLongTermPlan #medicalcommunication #imaging #MedTech #HealthcareIT'

[petekand] 15/10/2019 23:06

Nice to see Texrad alive and kicking. I for one will be over the moon when/if they can close a first commercial contract where it's actually embedded somewhere.

[ducatiman] 15/10/2019 20:25

Last update stated significant growth. Let's hope that can be proved up in the forthcoming results! We do indeed require another full update, hopefully they are waiting for something. More Jam tomorrow will not suffice.

[digger2779] 15/10/2019 20:14

We could do with an update from company considering the big push for the exhibition and then nothing.

[ducatiman] 15/10/2019 19:49

Good find LR2, continuing research support for Texrad. Commercial breakthrough needed though. We can only hope.

[lr2] 15/10/2019 18:25

A study highlighting the potential of TexRAD analysis of PET/CT in adults with neuro-endocrine cancers treated with Lutetium Dotatate - presented at EANM-2019 in Barcelona!



A study on the application of TexRAD texture analysis on Dixon sequence from PET-MRI examination in primary colorectal cancer can potentially increase the utility of PET/MRI was presented at EANM-2019 in Barcelona!

[dave4545] 15/10/2019 10:22

Easy money for mm's, they sell at 1.2p do not move then wait a while and on cue once one sells at 1.16p they all do and mm gets it all back, it's not fortunes but they do this in thousands of stocks who are quiet while keeping their main attention to the pump and dump stocks with the serious volumes

[petekand] 14/10/2019 22:04

I don't think any major mm manipulation is at play, rather someone is still offloading the placing shares as close as possible to the 1.2p price.
You would ideally want some follow-through from the company after the hype of the Bleepa launch and subsequent placing. But all seems a little quite on the western front.
I have a feeling the good doctor is up to something and we'll hear from him soon.

[ducatiman] 14/10/2019 15:15

Thank you LR2 but I have sufficient!

[lr2] 14/10/2019 14:14

And still 375k at 1.195p available to buy Duc. Go on, you know you want to.

Oh, and they'll take 600k off you at 1.1524p if you want (1.163p for smaller amounts).

[sonie01] 14/10/2019 13:42

MMs manipulating this?

[ducatiman] 14/10/2019 13:41

Not good when a 500k buy doesn't budge the mms.

[lr2] 13/10/2019 13:34

Hi Ged, nothing special to find that. I do a regular search for new TexRAD research occurrences and up it popped. It was Singapore that made it special. I don't think I've seen any TexRAD related results from Singapore before.

[ged5] 13/10/2019 11:13

Thanks seppin, good to see 'someone on the ball'.

[seppin] 13/10/2019 09:59

Hi Ged,

When I met board in February AR confirmed that Texrad is currently contracted and revenue earning in 60 locations globally for research purposes.

[ged5] 13/10/2019 09:29

So you like a little light reading, LR2? How did you find that?

So TexRAD used in Singapore and it works!

[lr2] 12/10/2019 23:07

Comparison of Manual versus Automated Measurement on T2 Weighted MRI Images Using TEXRAD Software



Introduction: In our previous study, entropy values of normal brain tissue generated with TEXRAD showed least variability. However, the manual drawing of region of interest (ROI) is time consuming. In this study, we compared manual versus automated ROI for entropy values of normal brain and tumor on T2 weighted MRI images.

...

Conclusion: In this study, manual and automated ROI methods result in significantly different entropy values for the tumour tissue.

[ged5] 12/10/2019 14:00

Yes.

Every reason to assume but we don't know for sure. I've just spent some time reading some of the references. Most of it beyond my comprehension but some of my Statistic studies came back to me. Fascinating stuff about CTTA or TexRAD. Some old articles that I'm sure LR2 will have linked somewhere on the old thread.

This from Reference 26 (2013) made me think why isn't it being used more?

CTTA represents a novel imaging approach that can potentially help address clinically important areas in cancer imaging. CTTA can be easily incorporated into imaging workflows at very little additional cost and increase the utility of images acquired in routine clinical practice. CTTA can potentially be used as a non-invasive imaging biomarker in tumour characterization, prognosis and treatment prediction, and response evaluation. With standardization and refinement of existing applications and further novel developments, CTTA is set to emerge as a valuable tool in oncologic imaging.

Then I thought isn't it being used in well over 30 establishments around the world?

Let's have a sought after commercial innovation in the strategic review.